New research reveals that people who discontinue popular slimming jabs like semaglutide or tirzepatide may regain shed pounds far faster than those who halt traditional diet and exercise plans.
Published data in a major health publication demonstrates that while obese people often shed about a fifth of their body weight while using the jabs, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing such medications need to be cognizant of the risk of quick weight regain when the medication ends," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery implies a return to original mass within about 18 months.
Comparing Approaches
The analysis, which reviewed 37 of studies involving over 9,000 of participants, contrasted the results of the injectable medications with older methods.
Researchers emphasize that individuals who lose weight through dieting usually see a slower weight regain—approximately 100 grams monthly—post-intervention.
The Reason for the Fast Rebound
Nutrition scientists believe the mechanism of the jabs accounts for the amplified rebound.
These medications copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous hormone, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' means hunger is uncontrolled, making excessive eating far more likely."
An Ongoing Issue?
The NHS recommend the jabs for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
A number of clinicians argue that, due to the likelihood of weight regain, the therapy should be considered life-long.
This view is echoed by pharmaceutical companies, who state that the results "underscore the long-term character of excess weight," similar to managing conditions like diabetes.
User Experiences
Individuals who have discontinued the jabs explain a intense resurgence of hunger.
"I experienced a switch flipping and I was suddenly ravenous," recalled an individual.
This difficulty is worsened if users have not established permanent dietary or behavioural modifications during treatment.
Significant Use
Survey data suggest that millions of people in the UK have tried these injections in the past year, with desire being substantial.
- Adoption is higher among females compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
Finally, clinicians caution that while these medications are effective tools for weight loss, they are not a magic cure and maintained weight loss likely depends on ongoing behavioural support.
